作者:Yogita K. Abhale、Amit V. Sasane、Abhijit P. Chavan、Saddam Husen Shekh、Keshav K. Deshmukh、Sujit Bhansali、Laxman Nawale、Dhiman Sarkar、Pravin C. Mhaske
DOI:10.1016/j.ejmech.2017.03.065
日期:2017.5
In the present study a series of 4-methyl-2-aryl-5-(2-aryl/benzyl thiazol-4-yl) oxazole (4a-v) have been synthesized and evaluated for their preliminary antitubercular, antimicrobial and cytotoxicity activity. Among all the synthesized compounds, 4v reported comparable activity against dormant M. tuberculosis H37Ra and M. bovis BCG strains with respect to standard drug rifampicin. The active compounds
在本研究中,已经合成了一系列的4-甲基-2-芳基-5-(2-芳基/苄基噻唑-4-基)恶唑(4a-v),并对其初步的抗结核,抗微生物和细胞毒性活性进行了评估。在所有合成的化合物中,相对于标准药物利福平,4v报告了对休眠的结核分枝杆菌H37Ra和牛分枝杆菌BCG菌株相当的活性。使用MTT分析法进一步测试了来自抗结核研究的活性化合物的抗HeLa,A549和PANC-1细胞系的抗增殖活性,并且在评估的最大浓度下未显示出明显的细胞毒性活性。此外,发现合成的化合物具有潜在的抗菌活性,MIC范围为2.1-26.8μg/ mL。高效力,